Ticagrelor and Clopidogrel on Platelet Effects in Chinese Patients With Stable Coronary Artery Disease

Last updated: December 20, 2021
Sponsor: First Affiliated Hospital of Harbin Medical University
Overall Status: Completed

Phase

4

Condition

Coronary Artery Disease

Thrombosis

Vascular Diseases

Treatment

N/A

Clinical Study ID

NCT04001894
20190515
  • Ages > 18
  • All Genders

Study Summary

Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor reduces thrombotic events in patients with coronary artery disease, but these benefits come at the expense of increased risk of bleeding when compared with aspirin monotherapy. Increased evidence showed that P2Y12 inhibitor monotherapy still maintain antiischemic efficacy while reducing the bleeding risk compared with DAPT. Therefore, the investigators performed this study to observe the efficacy of ticagrelor in comparison to clopidogrel in Chinese patients with stable CAD.

Eligibility Criteria

Inclusion

Inclusion Criteria:•

  • Aged ≥18 years
  • Subjects had documented with stable CAD
  • Women were required to be postmenopausal or surgically sterile
  • Patients were required to discontinue clopidogrel or ticagrelor at least 14 daysbefore randomization
  • Patients were required to discontinue aspirin at least 14 days before randomization.

Exclusion

Exclusion Criteria:

  • Acute coronary syndrome
  • Planned use of glycoprotein IIb/IIIa receptor inhibitors, adenosine diphosphate (ADP)receptor antagonists other than the study medication, or anticoagulant therapy duringthe study period
  • Platelet count <10×10^4/μL
  • Hstory of bleeding tendency
  • Diagnosed as respiratory or circulatory instability
  • Allergy to ticagrelor or clopidogrel

Study Design

Total Participants: 50
Study Start date:
July 02, 2019
Estimated Completion Date:
December 09, 2020

Study Description

Ticagrelor is a novel, direct-acting, reversibly binding P2Y12 receptor antagonist. When related with clopidogrel, ticagrelor exhibits a more potent and more predictable antiplatelet effect with a faster onset and offset of action. Current guidelines give a recommendation on the use of dual antiplatelet therapy support ticagrelor 90 mg twice daily over clopidogrel 75 mg daily in addition to aspirin in CAD patients. However, increasing evidence showed ticagrelor increased the risk of bleeding. Recent studies showed that P2Y12 inhibitor monotherapy still maintain antiischemic efficacy while reducing the bleeding risk compared with DAPT. So the investigators performed this randomized, single-blind, crossover clinical trial to observe the effects of standard-dose ticagrelor and standard-dose clopidogrel on platelet reactivity in Chinese patients with stable CAD.

Connect with a study center

  • Thrombelastogram

    Harbin, Heilongjiang 150001
    China

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.